Polymorphism of the methylentetrahydrofolatereductase (MTHFR) gene in patients with arterial hypertension

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Patients with arterial hypertension (AH) have an elevated risk of developing atherothrombotic complications, therefore it is important to reveal the genotypes associated with these complications, and to investigate how they are related to the other risk factors. The present study included 82 AH patients at stage II and III (male, Russian nationals, average age 52). The following analyses were performed: Clin. analysis of the blood, general analysis of the urine, lipid spectrum, plasma electrolytes, creatinine, glucose, electrocardiography, echocardioscopy, examination of the eye vessels, ultrasound examination of the carotid arteries, microalbuminuria. Other risk factors were taken into consideration (hereditary predisposition, smoking, obesity). The C677T (Glu222Ala) polymorphism of the MTHFR gene was detected with two methods: polymerase chain reaction and restrictase reaction. The control group for C677T polymorphism detection included 175 healthy Russian donors aged 18 to 50. Statistical significance of the differences was probed with the χ2 criterion. The С allele of MTHFR gene was found in 74% of cases, and the T allele in 26% of cases. The genotypes ratios were as follows: CC - 57% (47 patients). CT - 34% (28 patients), TT - 9% (7 patients). In the control group, the frequency of the С allele was 70%, of the T allele - 30%, CC genotype - 49% (85 people). CT - 42% (73 people), TT - 9% (17 people). Polymorphism of the MTHFR gene was independent of such risk factors as smoking, dyslipidemia, obesity, diabetes mellitus, but hereditary predisposition to AH is encountered significantly more seldom in the group of CC homozygotes that in the CT and TT groups (p=0.04). Among the target organ pathology in AH, retinal angiopathy, hypertrophy of the left ventricle and microalbuminuria were found to be independent of the MTHFR gene polymorphism, whereas carotid arteries atherosclerosis had a significantly lower incidence in the group of TT homozygotes as compared to patients with CC and CT genotypes (p=0.03). The MTHFR gene polymorphism did not affect the incidence of associated Clin. complications, such as obliterating atherosclerosis of the lower extremity vessels, ischemic heart disease, chronic heart failure, and acute insufficiency of cerebral circulat.

About the authors

T. Yu. Kuznetsova

Karelian scientific medical center NWB RAMS

Author for correspondence.
Email: shabanov@mail.rcom.ru
Russian Federation, Petrozavodsk

I. P. Dudanov

Karelian scientific medical center NWB RAMS

Email: shabanov@mail.rcom.ru

член-корреспондент РАМН

Russian Federation, Petrozavodsk

V. N. Bochkov

MSU

Email: shabanov@mail.rcom.ru

Faculty of findamental Med.

Russian Federation, Moscow

L. M. Samokhodskaja

MSU

Email: shabanov@mail.rcom.ru

Faculty of findamental Med.

Russian Federation, Moscow

N. V. Russkikh

Karelian scientific medical center NWB RAMS

Email: shabanov@mail.rcom.ru
Russian Federation, Petrozavodsk

D. V. Gavrilov

Karelian scientific medical center NWB RAMS

Email: shabanov@mail.rcom.ru
Russian Federation, Petrozavodsk

References

  1. Спиридонов М. Г., Степанов В. А., Пузырев В. П. О роли полиморфных вариантов гена 5,10-метилентетрагидрофолатредуктазы (MTHFR) в патогенезе сердечно-сосудистых заболеваний // Клин. мед. 2001. № 2. С. 10-16.
  2. Anderson J. L., King G. J., Thomson M. J. et al. A mutation in the methylenetetrahydrofolate reductase gene is not associated with increased risk for coronary artery disease or myocardial infarction // J. of the Am. Coll. of Cardiol. 1997. Vol. 30. № 5. P. 1206-1211.
  3. Boushey C. J., Beresford S. A., Omenn G. S. et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes // J. Am. Med. Assoc. 1995. Vol. 274. P. 1049-1057.
  4. Brattström L.. Wilcken D. E., Ohrvik J. et al. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a metaanalysis // Circulat. 1998. Vol. 98. № 23. P. 2520-2526.
  5. Brattström L., Wilcken D. Homocysteine and cardiovascular disease: cause or effect? // Am. J. of Clin. Nutrit. 2000. Vol. 72. № 2. P. 315-323.
  6. Castro R., Rivera 1., Ravasco P. et al. 5,10- Methylenetetrahydrofolate reductase 677CT and 1298A→C mutations are genetic determinants of elevated homocysteine // QJM. 2003. Vol. 94. № 4. P. 297-303.
  7. Christen W. G., Ajani U. A., Glynn R. J. et al. Blood levels of homocysteine and increased risks of cardiovascular disease: causal or casual? // Arch. Intern. Med. 2000. Vol. 160. P. 422-434.
  8. Danesh J., Lewington S. Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies // J. Cardiovasc. Risk. 1998. Vol. 5. P. 229-232.
  9. De Bree A., Verschuren W. M., Blom H. J. Biological cardiovascular risk factors and plasma homocysteine levels in the general Dutch population // Atheroscler. 2001. Vol. 154. P. 513-514.
  10. De Bree A., Verschuren W. M. M., Kromhout D. et al. Homocysteine Determinants and the Evidence to What Extent Homocysteine Determines the Risk of Coronary Heart Disease // Pharmacol. Rev. 2002. Vol. 54. № 4. P. 599-618.
  11. De Bree A., van der Put N. M., Mennen L. I. et al. Prevalences of hyperhomocysteinemia, unfavorable cholesterol profile and hypertension in European populations // Eur. J. of Clin. Nutrit. 2005. Vol. 59. № 4. P. 480-488.
  12. Eikelboom J. W., Lonn E., Genest J. Jr. et al. Homocyst(e)ine and Cardiovascular Disease: A Critical Review of the Epidemiologic Evidence // Ann. Intern. Med. 1999. Vol. 131. № 5. P. 363-375.
  13. Folsom A. R., Nieto F. J., McGovern P. G. et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study // Circulat. 1998. Vol. 98. № 3. P. 204-210.
  14. Ford E. S., Smith S. J., Stroup D. F. et al. Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies // Int. J. Epidemiol. 2002. Vol. 31. P. 59-70.
  15. Frederiksen J., Juul K., Grande P. et al. Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and case-control studies from the Copenhagen City Heart Study // Blood. 2004. Vol. 104. № 10. P. 3046-3051.
  16. Friso S., Girelli D., Trabetti E. et al. A1298C methylenetetrahydrofolate reductase mutation and coronary artery disease: relationships with C677T polymorphism and homocysteine/folate metabolism // Clin. & Exp. Med. 2002. Vol. 2. № 1. P. 7-12.
  17. Frosst P., Blom H. J., Milos R. et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase // Nat. Genet. 1995. Vol. 10. P. 111-113.
  18. Gasparovic J., Raslova K., Basistova Z. et al. Effect of C677T methylenetetrahydrofolate reductase gene polymorphism on plasma homocysteine levels in ethnic groups // Physiol. Res. 2004. Vol. 53. № 2. P. 215-218.
  19. Girelli D., Friso S., Trabetti E. et al. Methylenetetrahydrofolate reductase C677T mutation, plasma homocysteine, and folate in subjects from northern Italy with or without angiographically documented severe coronary atherosclerotic disease: evidence for an important genetic-environmental interaction // Blood. 1998. Vol. 91. № 11. P. 4158-4163.
  20. Girelli D., Martinelli N., Pizzolo F. et al. The Interaction between MTHFR 677 CT Genotype and Folate Status Is a Determinant of Coronary Atherosclerosis Risk // J. Nutr. 2003. Vol. 133. P. 1281-1285.
  21. Heux S., Morin F., Lea R. A. et al. The methylentetrahydrofolate reductase gene variant (C677T) as a risk factor for essential hypertension in Caucasians // Hyper. Res. 2004. Vol. 27. № 9. P. 663-667.
  22. Huang Y., Zhao Y. Y., Li S. Hyperhomocysteine, methylenetetrahydrofolate reductase gene, and other risk factors in ischemic stroke // Zhonghua Yi Xue Za Zhi. 2002. Vol. 82. № 2. P. 119-122.
  23. Husemoen L. L., Thomsen T. F., Fenger M. et al. Contribution of thermolabile methylenetetrahydrofolate reductase variant to total plasma homocysteine levels in healthy men and women // Genet. Epidemiol. 2003. Vol.
  24. № 4. P. 322-330. 24. Jones G. T., Harris E. L., Phillips L. V. et al. The methylenetetrahydrofolate reductase C677T polymorphism does not associate with susceptibility to abdominal aortic aneurysm // Eur. J. of Vascular & Endovascular Surgery. 2005. Vol. 30. № 2. P. 137-142.
  25. Kadziela J., Janas J., Dzielinska Z. et al. The C677T mutation in methylenetetrahydrofolate reductase gene, plasma homocysteine concentration and the risk of coronary artery disease // Kardiol. Pol. 2003. Vol. 59. № 7. P. 17-26.
  26. Kark J. D., Sinnreich R., Rosenberg I. H. et al. Plasma Homocysteine and Parental Myocardial Infarction in Young Adults in Jerusalem // Circulat. 2002. Vol. 105. P. 2725.
  27. Kawamoto R., Kohara K., Tabara Y. et al. An association of 5,10-methylenetetrahydrofolate reductase (MTHFR) gene polymorphism and common carotid atherosclerosis // J. Hum. Genet. 2001. Vol. 46. № 9. P. 506-510.
  28. Kelemen L. E., Anand S. S., Hegele R. A. et al. Associations of plasma homocysteine and the methylenetetrahydrofolate reductase C677T polymorphism with carotid intima media thickness among South Asian, Chinese and European Canadians // Atheroscler. 2004. Vol. 176. № 2. P. 361-370.
  29. Klerk M., Verhoef P., Clarke R. et al. MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis // JAMA. 2002. Vol. 288. № 16. P. 2023-2031.
  30. Kluijtmans L. A., Kastelein J. J., Lindemans J. et al. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease // Circulat. 1997. Vol. 96. P. 2573-2577.
  31. Kluijtmans L. A., Whitehead A. S. Methylenetetrahydrofolate reductase genotypes and predisposition to atherothrombotic disease; evidence that all three MTHFR C677T genotypes confer different levels of risk // Eur. Heart J. 2001. Vol. 22. № 4. P. 294-299.
  32. Kolling K., Ndrepepa G., Koch W. et al. Methylenetetrahydrofolate reductase gene C677T and A1298C polymorphisms, plasma homocysteine, folate, and vitamin B12 levels and the extent of coronary artery disease // Am. J. Cardiol. 2004. Vol. 93. № 10. P. 1201-1206.
  33. Lewis S. J., Ebrahim S., Smith G. D. Meta-analysis of MTHFR 677C→T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? // BMJ. 2005. Vol. 331. P. 1053.
  34. Li Z., Sun L., Zhang H. et al. Elevated Plasma Homocysteine Was Associated With Hemorrhagic and Ischemic Stroke, but Methylenetetrahydrofolate Reductase Gene C677T Polymorphism Was a Risk Factor for Thrombotic Stroke. A Multicenter Case-Control Study in China // Stroke. 2003. Vol. 34. P. 2085.
  35. Lievers K. J., Boers G. H., Verhoef P. et al. A second common variant in the methylenetetrahydrofolate reductase (MTHFR) gene and its relationship to MTHFR enzyme activity, homocysteine, and cardiovascular disease risk // J. Mol. Med. 2001. Vol. 79. № 9. P. 522-528.
  36. Lim P. S., Hung W. R., Wei Y. H. Polymorphism in methylenetetrahydrofolate reductase gene: its impact on plasma homocysteine levels and carotid atherosclerosis in ESRD patients receiving hemodialysis // Nephron. 2001. Vol. 87. № 3. P. 249-256.
  37. Lim U., Cassano P. A. Homocysteine and Blood Pressure in the Third National Health and Nutrition Examination Survey 1988-1994// Am. J. Epidemiol. 2002. Vol. 156. P. 1105-1113.
  38. Lim U., Peng K., Shane B. et al. Polymorphisms in cytoplasmic serine hydroxymethyltransferase and methylenetetrahydrofolate reductase affect the risk of cardiovascular disease in men // J. Nutr. 2005. Vol. 135. № 8. P. 1989-1994
  39. Liu C. S., Chiang H. C., Chen H. W. Methylene tetrahydrofolate reductase polymorphism determines the plasma homocysteine-lowering effect of large-dose folic acid supplementation in patients with cardiovascular disease // Nutr. 2004. Vol. 20. № 11-12. P. 974-978.
  40. Mager A., Battler A., Birnbaum Y. et al. Plasma homocysteine, methylenetetrahydrofolate reductase genotypes, and age at onset of symptoms of myocardial ischemia // Am. J. of Cardiol. 2002. Vol. 89. № 8. P. 919-923.
  41. Mager A., Koren-Morag N., Shohat M. et al. Family history, plasma homocysteine, and age at onset of symptoms of myocardial ischemia in patients with different methylenetetrahydrofolate reductase genotypes // Am. J. of Cardiol. 2005. Vol. 95. № 12. P. 1420-1424.
  42. Meleady R., Ueland P. M., Blom H. et al. Thermolabile methylenetetrahydrofolate reductase, homocysteine, and cardiovascular disease risk: the European Concerted Action Project // Am. J. of Clin. Nutrit. 2003. Vol. 77. № 1. P. 63-70.
  43. Morita H., Taguchi J., Kurihara H. et al. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease // Circulat. 1997. Vol. 95. № 8. P. 2032-2036.
  44. Mueller T., Marschon R., Dieplinger B. et al. Factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations are not associated with chronic limb ischemia: the Linz Peripheral Arterial Disease (LIPAD) study // J. of Vasc. Surgery. 2005. Vol. 41. № 5. P. 808-815.
  45. Nakai K., Itoh C., Nakai K. et al. Correlation between C677T MTHFR gene polymorphism, plasma homocysteine levels and the incidence of CAD // Am. J. Cardiovasc. Drugs. 2001. Vol. 1. № 5. P. 353-361.
  46. Nygard O., Vollset S. E., Refsum H. et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine study // J. Am. Med. Assoc. 1995. Vol. 274. P. 1526-1533.
  47. Pinto X., Vilaseca M. A., Garcia-Giralt N. et al. Homocysteine and the MTHFR 677C—>T allele in premature coronary artery disease. Case control and family studies // Eur. J. Clin. Invest. 2001. Vol. 31. № 1. P. 24-30.
  48. Ravera M., Viazzi F., Berruti V. et al. 5,10-Methylenetetrahydrofolate reductase polymorphism and early organ damage in primary hypertension // Am. J. Hyper. 2001. Vol. 14. № 4. Pt. 1. P. 371-376.
  49. Refsum H., Ueland P. M. Recent data are not in conflict with homocysteine as a cardiovascular risk factor // Curr. Opin. Lipidol. 1998. Vol. 9. P. 533-539.
  50. Rodriguez-Esparragon F., Hernandez-Perera O., Rodriguez-Perez J. C. et al. The effect of methylenetetrahydrofolate reductase C677T common variant on hypertensive risk is not solely explained by increased plasma homocysteine values // Clin. Exp. Hyper. 2003. Vol. 25. № 4. P. 209-220.
  51. Russo G. T., Friso S., Jacques P. F. et al. Age and Gender Affect the Relation between Methylenetetrahydrofolate Reductase C677T Genotype and Fasting Plasma Homocysteine Concentrations in the Framingham Offspring Study Cohort // J. Nutr. 2003. Vol. 133. P. 3416-3421.
  52. Schnyder G., Roffi M., Flammer Y. et al. Association of plasma homocysteine with restenosis after percutaneous coronary angioplasty // Eur. Heart J. 2001. Vol. 23. № 9. P. 726-733.
  53. Spotila L. D., Jacques P. F., Berger P. B. et al. Age dependence of the influence of methylenetetrahydrofolate reductase genotype on plasma homocysteine level // Am. J. Epidemiol. 2003. Vol. 158. № 9. P. 871-877.
  54. Sun J., Xu Y., Xue J. et al. Methylenetetrahydrofolate reductase polymorphism associated with susceptibility to coronary heart disease in Chinese type 2 diabetic patients // Mol. Cell. Endocrinol. 2005. Vol. 229. № 1–2. P. 95–101.
  55. Sundström J., Sullivan L., D'Agostino R. B. et al. Plasma Homocysteine, Hypertension Incidence, and Blood Pressure Tracking The Framingham Heart Study // Hypertens. 2003. Vol. 42. P. 1100.
  56. Tanis B. C., Blom H. J., Bloemenkamp D. G. Folate, homocysteine levels, methylenetetrahydrofolate reductase (MTHFR) 677C→T variant, and the risk of myocardial infarction in young women: effect of female hormones on homocysteine levels // J. Thromb. Haemost. 2004. Vol. 2. № 1. P. 35-41.
  57. Taylor L. M., DeFrang R. D., Harris E. J. et al. The association of elevated plasma homocyst(e)- ine with progression of symptomatic peripheral arterial disease // J. Vasc. Surg. 1991. Vol. 13. P. 128-136.
  58. Tsai M. Y., Welge B. G., Hanson N. Q. et al. Genetic causes of mild hyperhomocysteinemia in patients with premature occlusive coronary artery diseases // Atheroscler. 1999. Vol. 143. № 1. P. 163-170.
  59. Tylicki L., Fodinger M., Puttinger H. et al. Methylenetetrahydrofolate reductase gene polymorphisms in essential hypertension relation: with the development of hypertensive end-stage renal disease // Am. J. Hypertens. 2005. Vol. 18. № 11. P. 1442-1448.
  60. Ueland P. M., Refsum H., Beresford S. A. et al. The controversy over homocysteine and cardiovascular risk // Am. J. Clin. Nutr. Vol. 72. P. 324-332.
  61. Van der Put N. M., van den Heuvel L. P., Steegers-Theunissen R. P. et al. Decreased methylene tetrahydrofolate reductase activity due to the 677C → T mutation in families with spina bifida offspring // J. Mol. Med. 1996. Vol. 74. P. 691-694.
  62. Verhoef P., Rimm E. B., Hunter D. J. et al. A common mutation in the methylenetetrahydrofolate reductase gene and risk of coronary heart disease: results among U. S. men // J. of the Am. Coll. of Cardiol. 1998. Vol. 32. № 2. P. 353-359.
  63. Wald D. S., Law M., Morris J. K. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis // BMJ. 2002. Vol. 325. P. 1202.
  64. Williams C., Kingwell B., Burke A. K. et al. Folic acid supplementation for 3 wk reduces pulse pressure and large artery stiffness independent of MTHFR genotype // Am. J. of Clin. Nutrit. 2005. Vol. 82. № 1. P. 26-31.
  65. Zhan S., Gao Y., Yin X. et al. A case-control study on the relationship between abnormal homocysteine metabolism and essential hypertension // Zhonghua Liu Xing Bing Xue Za Zhi. 2000. Vol. 21. № 3. P. 194-197.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.